Daewoong Pharmaceutical Reaches Sales of KRW 1.16 Trillion in 2022, Fexuclue Leads The Highest Revenue
PR NewswireFeb 20, 2023
- Hitting a record high sale with business profits of KRW 106 billion and net profits of KRW 80.1 billion according to the accounting of 2022 - Not only stable positioning of Fexuclue but also achievement obtaining a permit of new medicine for Envlo SEOUL, South Korea, Feb. 20, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Seng-ho Jeon, Chang-jae Lee) announced its 2022 annual report. On a standalone basis, sales increased from the previous year by 10.1% to KRW 1.16 trillion with busin